CJC-1295 (DAC)
Research Grade
$85
$85.00
1 × $85.00 pick 2 and save $8.50
Buy More Save More
Same day dispatch · free express shipping over $250
Certificates of Analysis
All certificates →Current batch · on shelf
98.82%
Purity by HPLC · identity confirmed by MS
22 August 2026
- Batch
- APL-CJCD10-2608-03
- Net content
- 10.13 mg
- Specification
- ≥98.0% purity · passes
Every batch is analysed in-house by HPLC and mass spectrometry and ships with a batch-specific Certificate of Analysis. Independent third-party verification is added to select batches; none is published for CJC-1295 (DAC) yet.
Molecular Details
Every batch is analysed in-house by HPLC & mass spectrometry and ships with a Certificate of Analysis; select batches are additionally verified by an independent third-party laboratory.
Usage & Storage
Description
GHRH analogue with albumin-binding Drug Affinity Complex. Approximately 8 day half-life, studied in sustained GH and IGF-1 elevation research.
- 29 amino acid GHRH analogue with Drug Affinity Complex
- Covalent albumin binding extends half-life to ~8 days
- Studied in sustained GH and IGF-1 elevation models
- DPP-4-resistant substitutions (D-Ala2, Gln8, Ala15, Leu27)
- Research Grade purity >=98%
CJC-1295 with DAC is a 29 amino acid growth hormone releasing hormone (GHRH) analogue bearing a Drug Affinity Complex — a maleimidopropionyl linker that forms a covalent bond with circulating serum albumin — identified by CAS number 863288-34-0. This albumin conjugation is the defining feature of the molecule: it shields the peptide from renal clearance and enzymatic degradation, extending the plasma half-life from roughly 30 minutes in the non-DAC form to approximately 8 days. Research has therefore studied the DAC variant in models of sustained growth hormone and IGF-1 elevation rather than the discrete pulses associated with Modified GRF (1-29), making the two forms distinct research tools rather than interchangeable ones. Like the non-DAC form it carries the D-Ala2, Gln8, Ala15 and Leu27 substitutions conferring dipeptidyl peptidase-4 resistance, and binds the GHRH receptor on anterior pituitary somatotrophs to initiate the G-protein coupled cascade through adenylyl cyclase, cAMP and protein kinase A. Supplied as a lyophilised white powder with a molecular weight of approximately 3647 Da and molecular formula C165H269N47O46. Supplied strictly for in-vitro laboratory research. Not for human or veterinary consumption.
Frequently Asked Questions
Is CJC-1295 (DAC) legal to buy in Australia?
CJC-1295 (DAC) is supplied strictly as a research chemical for in-vitro laboratory use. It is not approved for human therapeutic use in Australia and is not for human or animal consumption. Researchers are responsible for compliance with Therapeutic Goods Administration (TGA) regulations and their institution's protocols.
What purity is CJC-1295 (DAC)?
We specify ≥98% purity — the High-Tier Research Grade (commercial RUO) standard. Every batch is analysed in-house by HPLC and mass spectrometry and ships with a Certificate of Analysis; select batches also undergo independent, third-party purity verification.
Does CJC-1295 (DAC) ship with a Certificate of Analysis (COA)?
Yes — every batch ships with a batch-specific COA documenting HPLC purity and mass-spectrometry identity. 3 CJC-1295 (DAC) batch certificates are published in full at australianpeptidelabs.com.au/certificates/cjc-1295-dac, so the analysis can be read before ordering and the batch number printed on the vial matched against it.
Where can I buy CJC-1295 (DAC) in Australia?
CJC-1295 (DAC) can be ordered here from Australian Peptide Labs for in-vitro research use, dispatched same day from within Australia with a COA included.
Do you provide dosing or administration guidance for CJC-1295 (DAC)?
No. As these compounds are supplied for laboratory research only, we do not provide dosing or administration protocols. Our research library covers reconstitution and concentration calculations for in-vitro work.